AI Protein Design Validates Life Sciences Opportunity as Citrini Names Stock Beneficiaries

Citrini Research's testing of Anthropic's Claude Science platform has provided real-world evidence that AI can accelerate drug discovery timelines, positioning life sciences companies to capitalize on faster protein design workflows. The research firm spent three months with Claude to design protein binders against scorpion neurotoxins, a process that compressed years of traditional work into weeks and delivered measurable binding results.